What’s the latest in immunotherapy?

A world leader in immunotherapy, Carl June, will discuss the emergence of a new form of targeted immunotherapy to treat cancer, Wednesday, May 14, 5:30 pm to 7 pm., at UC San Diego.

Carl June, MD

June, a professor of immunotherapy at the University of Pennsylvania, will discuss his pioneering work and also the barriers and challenges to bring this paradigm-shifting treatment into routine medical practice. His presentation is titled “Targeted Immunotherapy to Revolutionize Cancer Treatment.”

Co-presented by the Center for Ethics in Science and Technology and the UC San Diego Helen Edison Lecture Series, with support from the Leukemia & Lymphoma Society, the seminar will be held in the Mandell Weiss Theatre of the La Jolla Playhouse at UC San Diego, 2910 La Jolla Village Drive, La Jolla, CA 92037.

This type of cell-based, targeted immunotherapy has become one of the most exciting new approaches to treating cancer, stimulating the biotechnology and pharma industries to develop the means to deliver the therapy to patients.

The treatment involves using the patient’s own T lymphocytes (a type of white blood cell) that are genetically engineered to attack the cancer.

When effective, the treatment of immunotherapy appears to be curative. June’s team was the first to use these engineered “T cells” to treat a young girl with acute leukemia. Now, more than18 months since her treatment, she remains cancer-free.

June will outline the barriers and challenges in bringing this paradigm-shifting treatment into routine medical practice, as applied in treating blood cancers, skin cancers and other previously untreatable cancers such as metastatic lung cancer.

As part of the Center for Ethics in Science and Technology Series, his presentation is the fifth themed on Siddhartha Mukherjee's 2010 Pulitzer-Prize winning book about cancer, “The Emperor of All Maladies.”

Blog post currently doesn't have any comments.

What's your story?

Share your accomplishments, advice, and goals for a chance to be featured.